|
1
|
Bettendorf O, Piffkò J and Bànkfalvi A:
Prognostic and predictive factors in oral squamous cell cancer:
Important tools for planning individual therapy? Oral Oncol.
40:110–119. 2004. View Article : Google Scholar
|
|
2
|
Fong D, Spizzo G, Gostner JM, Gastl G,
Moser P, Krammel C, Gerhard S, Rasse M and Laimer K: TROP2: A novel
prognostic marker in squamous cell carcinoma of the oral cavity.
Mod Pathol. 21:186–191. 2008. View Article : Google Scholar
|
|
3
|
Markolovic S, Wilkins SE and Schofield CJ:
Protein hydroxylation Catalyzed by 2-oxoglutarate-dependent
oxygenases. J Biol Chem. 290:20712–20722. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ploumakis A and Coleman ML: OH, the places
you'll go! hydroxylation, gene expression, and cancer. Mol Cell.
58:729–741. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klose RJ, Kallin EM and Zhang Y:
JmjC-domain-containing proteins and histone demethylation. Nat Rev
Genet. 7:715–727. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gilkes DM, Chaturvedi P, Bajpai S, Wong
CC, Wei H, Pitcairn S, Hubbi ME, Wirtz D and Semenza GL: Collagen
prolyl hydroxylases are essential for breast cancer metastasis.
Cancer Res. 73:3285–3296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Myllyharju J: Prolyl 4-hydroxylases, the
key enzymes of collagen biosynthesis. Matrix Biol. 22:15–24. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee KA, Lynd JD, O'Reilly S, Kiupel M,
McCormick JJ and LaPres JJ: The biphasic role of the
hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating
tumor-forming potential. Mol Cancer Res. 6:829–842. 2008.
View Article : Google Scholar
|
|
9
|
Epstein AC, Gleadle JM, McNeill LA,
Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI,
Dhanda A, et al: C. elegans EGL-9 and mammalian homologs define a
family of dioxygenases that regulate HIF by prolyl hydroxylation.
Cell. 107:43–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bruick RK and McKnight SL: A conserved
family of prolyl-4-hydroxylases that modify HIF. Science.
294:1337–1340. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Højfeldt JW, Agger K and Helin K: Histone
lysine demethylases as targets for anticancer therapy. Nat Rev Drug
Discov. 12:917–930. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Black JC, Manning AL, Van Rechem C, Kim J,
Ladd B, Cho J, Pineda CM, Murphy N, Daniels DL, Montagna C, et al:
KDM4A lysine demethylase induces site-specific copy gain and
rereplication of regions amplified in tumors. Cell. 154:541–555.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takaluoma K, Lantto J and Myllyharju J:
Lysyl hydroxylase 2 is a specific telopeptide hydroxylase, while
all three isoenzymes hydroxylate collagenous sequences. Matrix
Biol. 26:396–403. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Terajima M, Yang Y, Sun L, Ahn YH,
Pankova D, Puperi DS, Watanabe T, Kim MP, Blackmon SH, et al: Lysyl
hydroxylase 2 induces a collagen cross-link switch in tumor stroma.
J Clin Invest. 125:1147–1162. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gilkes DM, Bajpai S, Wong CC, Chaturvedi
P, Hubbi ME, Wirtz D and Semenza GL: Procollagen lysyl hydroxylase
2 is essential for hypoxia-induced breast cancer metastasis. Mol
Cancer Res. 11:456–466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D
and Semenza GL: Hypoxia-inducible factor 1 (HIF-1) promotes
extracellular matrix remodeling under hypoxic conditions by
inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol
Chem. 288:10819–10829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gjaltema RAF, de Rond S, Rots MG and Bank
RA: Procollagen lysyl hydroxylase 2 expression is regulated by an
alternative downstream transforming growth factor b-1 activation
mechanism. J Biol Chem. 290:28465–28476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noda T, Yamamoto H, Takemasa I, Yamada D,
Uemura M, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M,
et al: PLOD2 induced under hypoxia is a novel prognostic factor for
hepatocellular carcinoma after curative resection. Liver Int.
32:110–118. 2012. View Article : Google Scholar
|
|
19
|
He JY, Wei XH, Li SJ, Liu Y, Hu HL, Li ZZ,
Kuang XH, Wang L, Shi X, Yuan ST, et al: Adipocyte-derived IL-6 and
leptin promote breast cancer metastasis via upregulation of lysyl
hydroxylase-2 expression. Cell Commun Signal. 16:100–118. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Levental KR, Yu H, Kass L, Lakins JN,
Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et
al: Matrix crosslinking forces tumor progression by enhancing
integrin signaling. Cell. 139:891–906. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Liu FY and Kirkwood KL: The
p38/MKP-1 signaling axis in oral cancer: Impact of tumor-associated
macrophages. Oral Oncol. 103:104591–104599. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Solinas G, Germano G, Mantovani A and
Allavena P: Tumor-associated macrophages (TAM) as major players of
the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ueki Y, Saito K, Iioka H, Sakamoto I,
Kanda Y, Sakaguchi M, Horii A and Kondo E: PLOD2 Is Essential to
functional activation of integrin β1 for invasion/metastasis in
head and neck squamous cell carcinomas. iScience. 23:1008502020.
View Article : Google Scholar
|
|
24
|
St John MA, Li Y, Zhou X, Denny P, Ho CM,
Montemagno C, Shi W, Qi F, Wu B, Sinha U, et al: Interleukin 6 and
interleukin 8 as potential biomarkers for oral cavity and
oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck
Surg. 130:929–935. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malhotra R, Patel V, Vaqué JP, Gutkind JS
and Rusling JF: Ultrasensitive electrochemical immunosensor for
oral cancer biomarker IL-6 using carbon nanotube forest electrodes
and multilabel amplification. Anal Chem. 82:3118–3123. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ferreira FO, Ribeiro FL, Batista AC, Leles
CR, de Cássia Gonçalves Alencar R and Silva TA: Association of CCL2
with lymph node metastasis and macrophage infiltration in oral
cavity and lip squamous cell carcinoma. Tumour Biol. 29:114–121.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sriuranpong V, Park JI, Amornphimoltham P,
Patel V, Nelkin BD and Gutkind JS: Epidermal growth factor
receptor-independent constitutive activation of STAT3 in head and
neck squamous cell carcinoma is mediated by the autocrine/paracrine
stimulation of the interleukin 6/gp130 cytokine system. Cancer Res.
63:2948–2956. 2003.PubMed/NCBI
|
|
28
|
Tanabe H, Takada Y, Minegishi D, Kurematsu
M, Masui T and Mizusawa H: Cell line individualization by STR
multiplex system in the cell bank found cross contamination between
ECV304 and EJ-1/T24. Tissue Cult Res Commun. 18:329–338. 1999.
|
|
29
|
Zhao M, Sano D, Pickering CR, Jasser SA,
Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, et
al: Assembly and initial characterization of a panel of 85
genomically validated cell lines from diverse head and neck tumor
sites. Clin Cancer Res. 17:7248–7264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Razidlo GL, Burton KM and McNiven MA:
Interleukin-6 promotes pancreatic cancer cell migration by rapidly
activating the small GTPase CDC42. J Biol Chem. 293:11143–11153.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu T, Ma H, Shi W, Duan J, Wang Y, Zhang
C, Li C, Lin J, Li S, Lv J, et al: Inhibition of STAT3 signaling
pathway by ursolic acid suppresses growth of hepatocellular
carcinoma. Int J Oncol. 51:555–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Misumi Y, Okamoto H, Sasaki J, Masuda N,
Ishii M, Shimokawa T, Hosomi Y, Okuma Y, Nagamata M, Ogura T, et
al: Phase I/II study of induction chemotherapy using carboplatin
plus irinotecan and sequential thoracic radiotherapy (TRT) for
elderly patients with limited-disease small-cell lung cancer
(LD-SCLC): TORG 0604. BMC Cancer. 17:377–385. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tominaga H, Setoguchi T, Shimada H, Nagano
S, Sasaki H, Ishidou Y, Sato M, Mizuno K, Inoue H and Komiya S:
Prognostic factors in patients with skeletal-related events at
non-small-cell lung cancer diagnosis. Mol Clin Oncol. 7:897–902.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song Y, Zheng S, Wang J, Long H, Fang L,
Wang G, Li Z, Que T, Liu Y, Li Y, et al: Hypoxia-induced PLOD2
promotes proliferation, migration and invasion via PI3K/Akt
signaling in glioma. Oncotarget. 8:41947–41962. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu Y, He MY, Zhu LF, Yang CC, Zhou ML,
Wang Q, Zhang W, Zheng YY, Wang DM, Xu ZQ, et al: Tumor-associated
macrophages correlate with the clinicopathological features and
poor outcomes via inducing epithelial to mesenchymal transition in
oral squamous cell carcinoma. J Exp Clin Cancer Res. 35:12–30.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Komohara Y, Jinushi M and Takeya M:
Clinical significance of macrophage heterogeneity in human
malignant tumors. Cancer Sci. 105:1–8. 2014. View Article : Google Scholar
|
|
38
|
Mori K, Hiroi M, Shimada J and Ohmori Y:
Infiltration of m2 tumor-associated macrophages in oral squamous
cell carcinoma correlates with tumor malignancy. Cancers (Basel).
3:3726–3739. 2011. View Article : Google Scholar
|
|
39
|
Pastushenko I, Brisebarre A, Sifrim A,
Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D,
Moers V, Lemaire S, et al: Identification of the tumour transition
states occurring during EMT. Nature. 556:463–468. 2018. View Article : Google Scholar : PubMed/NCBI
|
